{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:05:15Z","timestamp":1790078715941,"version":"4.0.1"},"reference-count":134,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R56AI135770"],"award-info":[{"award-number":["R56AI135770"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI093450"],"award-info":[{"award-number":["R01AI093450"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host,<ns4:italic>Mastomys natalensis<\/ns4:italic>, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO\u2019s TPP for an LASV vaccine.<\/ns4:p>","DOI":"10.12688\/f1000research.16989.1","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T12:20:18Z","timestamp":1548937218000},"page":"134","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Lassa virus diversity and feasibility for universal prophylactic vaccine"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-5116","authenticated-orcid":false,"given":"Igor S.","family":"Lukashevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Paessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"670-6","DOI":"10.4269\/ajtmh.1970.19.670","article-title":"Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.","volume":"19","author":"J Frame","year":"1970","journal-title":"Am J Trop Med Hyg."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"695-6","DOI":"10.4269\/ajtmh.1970.19.695","article-title":"An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report.","volume":"19","author":"J Troup","year":"1970","journal-title":"Am J Trop Med Hyg."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1851-74","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present, and future of arenavirus taxonomy.","volume":"160","author":"S Radoshitzky","year":"2015","journal-title":"Arch Virol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"692-4","DOI":"10.4269\/ajtmh.1970.19.692","article-title":"Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus.","volume":"19","author":"R Speir","year":"1970","journal-title":"Am J Trop Med Hyg."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"263-5","DOI":"10.1126\/science.185.4147.263","article-title":"Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.","volume":"185","author":"T Monath","year":"1974","journal-title":"Science."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"189-212","DOI":"10.1016\/B978-1-78548-277-9.50011-5","article-title":"Mice and Men: an Evolutionary History of Lassa Fever.","author":"A Lalis","year":"2018","journal-title":"Biodivers Evol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"69-78","DOI":"10.1007\/978-3-642-71726-0_3","article-title":"Epidemiology and control of Lassa fever.","volume":"134","author":"J McCormick","year":"1987","journal-title":"Curr Top Microbiol Immunol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"283-97","DOI":"10.1089\/15303660160025912","article-title":"Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals.","volume":"1","author":"A Demby","year":"2001","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref-9","doi-asserted-by":"publisher","DOI":"10.1038\/srep21977","article-title":"Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea.","volume":"6","author":"E Fichet-Calvet","year":"2016","journal-title":"Sci Rep."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"646-55","DOI":"10.1111\/2041-210X.12549","article-title":"Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: A case study of Lassa fever.","volume":"7","author":"D Redding","year":"2016","journal-title":"Methods Ecol Evol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"276-88","DOI":"10.1080\/20477724.2017.1369643","article-title":"Understanding the cryptic nature of Lassa fever in West Africa.","volume":"111","author":"R Gibb","year":"2017","journal-title":"Pathog Glob Health."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"e1006073","DOI":"10.1371\/journal.ppat.1006073","article-title":"When Viruses Don't Go Viral: The Importance of Host Phylogeographic Structure in the Spatial Spread of Arenaviruses.","volume":"13","author":"S Gryseels","year":"2017","journal-title":"PLoS Pathog."},{"key":"ref-13","first-page":"441-4","article-title":"Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa.","volume":"55","author":"H Wulff","year":"1977","journal-title":"Bull World Health Organ."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"2008-12","DOI":"10.3201\/eid1512.090864","article-title":"Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania.","volume":"15","author":"S G\u00fcnther","year":"2009","journal-title":"Emerg Infect Dis."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"1921-4","DOI":"10.3201\/eid1710.10452","article-title":"Novel arenavirus, Zambia.","volume":"17","author":"A Ishii","year":"2011","journal-title":"Emerg Infect Dis."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"249-56","DOI":"10.1016\/j.virol.2014.12.011","article-title":"Gairo virus, a novel arenavirus of the widespread Mastomys natalensis: Genetically divergent, but ecologically similar to Lassa and Morogoro viruses.","volume":"476","author":"S Gryseels","year":"2015","journal-title":"Virology."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"694-7","DOI":"10.3201\/eid2204.150155","article-title":"Arenavirus Diversity and Phylogeography of Mastomys natalensis Rodents, Nigeria.","volume":"22","author":"A Olayemi","year":"2016","journal-title":"Emerg Infect Dis."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s13071-018-2991-5","article-title":"Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria.","volume":"11","author":"A Olayemi","year":"2018","journal-title":"Parasit Vectors."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"4137-50","DOI":"10.1111\/j.1365-294X.2012.05663.x","article-title":"Complex patterns of host switching in New World arenaviruses.","volume":"21","author":"N Irwin","year":"2012","journal-title":"Mol Ecol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"43-7","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa fever in West Africa: evidence for an expanded region of endemicity.","volume":"59 Suppl 2","author":"N Sogoba","year":"2012","journal-title":"Zoonoses Public Health."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"25280","DOI":"10.1038\/srep25280","article-title":"New Hosts of The Lassa Virus.","volume":"6","author":"A Olayemi","year":"2016","journal-title":"Sci Rep."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1271-5","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences.","volume":"327","author":"J Richmond","year":"2003","journal-title":"BMJ."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1371\/journal.pntd.0000388","article-title":"Risk Maps of Lassa Fever in West Africa.","volume":"3","author":"E Fichet-Calvet","year":"2009","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"343-51","DOI":"10.1016\/j.coviro.2013.04.007","article-title":"Vaccines for viral hemorrhagic fevers--progress and shortcomings.","volume":"3","author":"D Falzarano","year":"2013","journal-title":"Curr Opin Virol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"20-6","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin.","volume":"314","author":"J McCormick","year":"1986","journal-title":"N Engl J Med."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"437-44","DOI":"10.1093\/infdis\/155.3.437","article-title":"A prospective study of the epidemiology and ecology of Lassa fever.","volume":"155","author":"J McCormick","year":"1987","journal-title":"J Infect Dis."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"456-64","DOI":"10.1093\/infdis\/155.3.456","article-title":"Clinical virology of Lassa fever in hospitalized patients.","volume":"155","author":"K Johnson","year":"1987","journal-title":"J Infect Dis."},{"key":"ref-28","first-page":"75-109","article-title":"Lassa fever.","volume":"262","author":"J McCormick","year":"2002","journal-title":"Curr Top Microbiol Immunol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"663-666","DOI":"10.1080\/14787210.2018.1512856","article-title":"Lassa fever outbreaks in Nigeria.","volume":"16","author":"G Akpede","year":"2018","journal-title":"Expert Rev Anti Infect Ther."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"262-264","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria.","volume":"108","author":"M Buba","year":"2018","journal-title":"Am J Public Health."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1201-1202","DOI":"10.1126\/science.359.6381.1201","article-title":"Nigeria hit by unprecedented Lassa fever outbreak.","volume":"359","author":"L Roberts","year":"2018","journal-title":"Science."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(18)30179-8","article-title":"Lassa fever and global health security.","volume":"18","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-33","article-title":"Annual review of diseases prioritized under the Research and Development Blueprint","year":"2017"},{"key":"ref-34","article-title":"Lassa Fever","year":"2018"},{"key":"ref-35","article-title":"Nigeria - Lassa Fever","year":"2017"},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"351-79","DOI":"10.2174\/138920206778948673","article-title":"Lassa Virus Genome.","volume":"7","author":"I Lukashevich","year":"2006","journal-title":"Curr Genomics."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"1157-61","DOI":"10.1128\/JCM.01891-10","article-title":"Current molecular epidemiology of Lassa virus in Nigeria.","volume":"49","author":"D Ehichioya","year":"2011","journal-title":"J Clin Microbiol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"738-50","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.","volume":"162","author":"K Andersen","year":"2015","journal-title":"Cell."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","article-title":"Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage.","volume":"6","author":"J Manning","year":"2015","journal-title":"Front Microbiol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"6992-7004","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains.","volume":"74","author":"M Bowen","year":"2000","journal-title":"J Virol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"609-18","DOI":"10.3201\/eid2104.141469","article-title":"Sequence variability and geographic distribution of Lassa virus, Sierra Leone.","volume":"21","author":"T Leski","year":"2015","journal-title":"Emerging Infect Dis."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"466-76","DOI":"10.3201\/eid0605.000504","article-title":"Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.","volume":"6","author":"S G\u00fcnther","year":"2000","journal-title":"Emerging Infect Dis."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"599-602","DOI":"10.3201\/eid2403.171905","article-title":"New Lineage of Lassa Virus, Togo, 2016.","volume":"24","author":"S Whitmer","year":"2018","journal-title":"Emerging Infect Dis."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"71-86","DOI":"10.1586\/erv.12.139","article-title":"The search for animal models for Lassa fever vaccine development.","volume":"12","author":"I Lukashevich","year":"2013","journal-title":"Expert Rev Vaccines."},{"key":"ref-45","doi-asserted-by":"crossref","first-page":"771-8","DOI":"10.1128\/IAI.37.2.771-778.1982","article-title":"Pathogenesis of Lassa virus infection in guinea pigs.","volume":"37","author":"P Jahrling","year":"1982","journal-title":"Infect Immun."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"4093-102","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.","volume":"25","author":"R Carrion","year":"2007","journal-title":"Vaccine."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"549-62","DOI":"10.1177\/0300985816677153","article-title":"Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus.","volume":"54","author":"T Bell","year":"2016","journal-title":"Vet Pathol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","article-title":"A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.","volume":"9","author":"D Safronetz","year":"2015","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"5-68","DOI":"10.1007\/978-3-642-71726-0_2","article-title":"Experimental studies of arenaviral hemorrhagic fevers.","volume":"134","author":"C Peters","year":"1987","journal-title":"Curr Top Microbiol Immunol."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"186-8","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.","volume":"330","author":"J Clegg","year":"1987","journal-title":"Lancet."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"374-9","DOI":"10.1016\/0035-9203(85)90386-4","article-title":"Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.","volume":"79","author":"P Jahrling","year":"1985","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"5890-903","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.","volume":"83","author":"S Baize","year":"2009","journal-title":"J Virol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422X-8-205","article-title":"Pathogenesis of lassa fever in cynomolgus macaques.","volume":"8","author":"L Hensley","year":"2011","journal-title":"Virol J."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"195-207","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections.","volume":"17","author":"J Prescott","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1316-27","DOI":"10.1093\/infdis\/jit004","article-title":"A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.","volume":"207","author":"D Safronetz","year":"2013","journal-title":"J Infect Dis."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"684-95","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.","volume":"18","author":"P Okokhere","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"e0122839","DOI":"10.1371\/journal.pone.0122839","article-title":"Novel mechanism of arenavirus-induced liver pathology.","volume":"10","author":"J Beier","year":"2015","journal-title":"PLoS One."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1399-402","DOI":"10.1136\/bmj.1.6073.1399","article-title":"Lassa fever in Panguma Hospital, Sierra Leone, 1973-6.","volume":"1","author":"E Keane","year":"1977","journal-title":"Br Med J."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"445-55","DOI":"10.1093\/infdis\/155.3.445","article-title":"A Case-Control Study of the Clinical Diagnosis and Course of Lassa Fever.","volume":"155","author":"J McCormick","year":"1987","journal-title":"J Infect Dis."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"S783-S789","DOI":"10.1093\/clinids\/11.Supplement_4.S783","article-title":"Clinical features of Lassa fever in Liberia.","volume":"11 Suppl 4","author":"J Frame","year":"1989","journal-title":"Rev Infect Dis."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"2797-801","DOI":"10.4049\/jimmunol.170.6.2797","article-title":"Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.","volume":"170","author":"S Mahanty","year":"2003","journal-title":"J Immunol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"401-7","DOI":"10.4269\/ajtmh.1986.35.401","article-title":"Lassa virus hepatitis: a study of fatal Lassa fever in humans.","volume":"35","author":"J McCormick","year":"1986","journal-title":"Am J Trop Med Hyg."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"1727-37","DOI":"10.1128\/JVI.77.3.1727-1737.2003","article-title":"Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation.","volume":"77","author":"I Lukashevich","year":"2003","journal-title":"J Virol."},{"key":"ref-64","first-page":"3-7","article-title":"Epidemiological and clinical description of Lassa fever in Jos, Nigeria.","volume":"13","author":"S Isa","year":"2013","journal-title":"High Med Res J."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fpubh.2018.00232","article-title":"Lassa Fever 2016 Outbreak in Plateau State, Nigeria-The Changing Epidemiology and Clinical Presentation.","volume":"6","author":"N Shehu","year":"2018","journal-title":"Front Public Health."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"6482-90","DOI":"10.1128\/JVI.02876-06","article-title":"Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues.","volume":"81","author":"R Carrion","year":"2007","journal-title":"J Virol."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"e1839","DOI":"10.1371\/journal.pntd.0001839","article-title":"Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation.","volume":"6","author":"D Asogun","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"1745-53","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018.","volume":"379","author":"K Siddle","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"e0006971","DOI":"10.1371\/journal.pntd.0006971","article-title":"Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria.","volume":"12","author":"O Oloniniyi","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"661-6","DOI":"10.4269\/ajtmh.1996.55.661","article-title":"Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea.","volume":"55","author":"J Ter Meulen","year":"1996","journal-title":"Am J Trop Med Hyg."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"e0006187","DOI":"10.1371\/journal.pntd.0006187","article-title":"Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden.","volume":"12","author":"E Mateer","year":"2018","journal-title":"PLoS Negl Trop Dis."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"2920-7","DOI":"10.1128\/JVI.02948-15","article-title":"Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection.","volume":"90","author":"N Yun","year":"2015","journal-title":"J Virol."},{"key":"ref-73","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01896-18","article-title":"Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.","volume":"9","author":"K Cashman","year":"2018","journal-title":"mBio."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"6777-83","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective Vaccine for Lassa Fever.","volume":"74","author":"S Fisher-Hoch","year":"2000","journal-title":"J Virol."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"189-97","DOI":"10.1586\/14760584.3.2.189","article-title":"Lassa fever vaccine.","volume":"3","author":"S Fisher-Hoch","year":"2014","journal-title":"Expert Rev Vaccines."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"2031-48","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of Lassa fever.","volume":"4","author":"N Yun","year":"2012","journal-title":"Viruses."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.","volume":"3","author":"H Hallam","year":"2018","journal-title":"NPJ Vaccines."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"1862-1872","DOI":"10.1093\/infdis\/jix201","article-title":"A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.","volume":"215","author":"A McElroy","year":"2017","journal-title":"J Infect Dis."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"153-5","DOI":"10.1007\/BF02122438","article-title":"Clinical, epidemiologic, and therapeutic aspects of Lassa fever.","volume":"175","author":"J McCormick","year":"1986","journal-title":"Med Microbiol Immunol."},{"key":"ref-80","first-page":"177-195","article-title":"Lassa fever","author":"J McCormick","year":"1999"},{"key":"ref-81","doi-asserted-by":"publisher","first-page":"2186-92","DOI":"10.1128\/JVI.74.5.2186-2192.2000","article-title":"Characterization of human CD4+ T-Cell clones recognizing conserved and variable epitopes of the lassa virus nucleoprotein.","volume":"74","author":"J ter Meulen","year":"2000","journal-title":"J Virol."},{"key":"ref-82","doi-asserted-by":"publisher","first-page":"134-43","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones.","volume":"321","author":"J Meulen","year":"2004","journal-title":"Virology."},{"key":"ref-83","doi-asserted-by":"publisher","first-page":"218-22","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.","volume":"133","author":"R Cross","year":"2016","journal-title":"Antiviral Res."},{"key":"ref-84","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.","volume":"7","author":"J Robinson","year":"2016","journal-title":"Nat Commun."},{"key":"ref-85","doi-asserted-by":"publisher","first-page":"8351-61","DOI":"10.1128\/JVI.00896-06","article-title":"Identification of protective Lassa virus epitopes that are restricted by HLA-A2.","volume":"80","author":"J Botten","year":"2006","journal-title":"J Virol."},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"600-5","DOI":"10.1016\/0042-6822(92)90514-P","article-title":"Generation of reassortants between African arenaviruses.","volume":"188","author":"I Lukashevich","year":"1992","journal-title":"Virology."},{"key":"ref-87","doi-asserted-by":"publisher","first-page":"13934-42","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.","volume":"79","author":"I Lukashevich","year":"2005","journal-title":"J Virol."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"1135-50","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever.","volume":"15","author":"I Lukashevich","year":"2016","journal-title":"Expert Rev Vaccines."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"3113-21","DOI":"10.4049\/jimmunol.180.5.3113","article-title":"Absence of CTL responses to early viral antigens facilitates viral persistence.","volume":"180","author":"A Schildknecht","year":"2008","journal-title":"J Immunol."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"251-7","DOI":"10.1016\/j.virol.2006.01.026","article-title":"Phylogeny and evolution of old world arenaviruses.","volume":"350","author":"S Emonet","year":"2006","journal-title":"Virology."},{"key":"ref-91","doi-asserted-by":"publisher","first-page":"125-38","DOI":"10.1016\/j.antiviral.2011.07.015","article-title":"Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.","volume":"92","author":"J Zapata","year":"2011","journal-title":"Antiviral Res."},{"key":"ref-92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1743-422X-10-52","article-title":"An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.","volume":"10","author":"J Zapata","year":"2013","journal-title":"Virol J."},{"key":"ref-93","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens7040084","article-title":"Improving the Breadth of the Host's Immune Response to Lassa Virus.","volume":"7","author":"J Zapata","year":"2018","journal-title":"Pathogens."},{"key":"ref-94","article-title":"WHO Target Product Profile for Lassa virus Vaccine","year":"2017"},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"233-48","DOI":"10.1016\/0168-1702(88)90033-0","article-title":"Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.","volume":"9","author":"D Auperin","year":"1988","journal-title":"Virus Res."},{"key":"ref-96","doi-asserted-by":"publisher","first-page":"5458-65","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.","volume":"78","author":"M Garbutt","year":"2004","journal-title":"J Virol."},{"key":"ref-97","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever.","volume":"2","author":"T Geisbert","year":"2005","journal-title":"PLoS Med."},{"key":"ref-98","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(79)90659-7","article-title":"Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus.","volume":"2","author":"M Kiley","year":"1979","journal-title":"Lancet."},{"key":"ref-99","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02230-17","article-title":"A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.","volume":"92","author":"X Carnec","year":"2018","journal-title":"J Virol."},{"key":"ref-100","doi-asserted-by":"publisher","first-page":"299-304","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.","volume":"345","author":"P Bredenbeek","year":"2006","journal-title":"Virology."},{"key":"ref-101","doi-asserted-by":"publisher","first-page":"1248-57","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.","volume":"29","author":"X Jiang","year":"2011","journal-title":"Vaccine."},{"key":"ref-102","doi-asserted-by":"publisher","first-page":"11677-85","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.","volume":"75","author":"P Pushko","year":"2001","journal-title":"J Virol."},{"key":"ref-103","doi-asserted-by":"publisher","first-page":"683-90","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.","volume":"36","author":"M Wang","year":"2018","journal-title":"Vaccine."},{"key":"ref-104","doi-asserted-by":"publisher","first-page":"16-9","DOI":"10.1126\/science.351.6268.16","article-title":"Unfilled Vials.","volume":"351","author":"J Cohen","year":"2016","journal-title":"Science."},{"key":"ref-105","doi-asserted-by":"publisher","first-page":"5246-54","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.","volume":"26","author":"I Lukashevich","year":"2008","journal-title":"Vaccine."},{"key":"ref-106","doi-asserted-by":"publisher","first-page":"3058-66","DOI":"10.1128\/JVI.03035-13","article-title":"Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.","volume":"88","author":"J Zapata","year":"2014","journal-title":"J Virol."},{"key":"ref-107","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7560.1000160","article-title":"Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.","volume":"3","author":"R Carrion","year":"2012","journal-title":"J Vaccines Vaccin."},{"key":"ref-108","doi-asserted-by":"publisher","first-page":"1445-52","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model.","volume":"30","author":"M Goicochea","year":"2012","journal-title":"Vaccine."},{"key":"ref-109","doi-asserted-by":"publisher","first-page":"179-88","DOI":"10.1016\/0042-6822(89)90525-4","article-title":"Protection of guinea pigs from lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of lassa virus.","volume":"171","author":"H Morrison","year":"1989","journal-title":"Virology."},{"key":"ref-110","doi-asserted-by":"publisher","first-page":"2902-11","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.","volume":"13","author":"K Cashman","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"ref-111","article-title":"Use of recombinant ML29 platform to generate polyvalent live-attenuated vaccines against lassa fever and other infectious diseases","author":"M Iwasaki","year":"2018"},{"key":"ref-112","doi-asserted-by":"publisher","first-page":"3473-8","DOI":"10.1073\/pnas.0900088106","article-title":"Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest.","volume":"106","author":"S Emonet","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-113","doi-asserted-by":"publisher","first-page":"2755-62","DOI":"10.1080\/21645515.2017.1306615","article-title":"Vaccines for epidemic infections and the role of CEPI.","volume":"13","author":"S Plotkin","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"ref-114","doi-asserted-by":"publisher","first-page":"519-27","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.","volume":"15","author":"K Ramsauer","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"ref-115","article-title":"Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS","year":"2018"},{"key":"ref-116","doi-asserted-by":"publisher","first-page":"31-47","DOI":"10.1016\/j.actbio.2018.08.033","article-title":"Engineering DNA vaccines against infectious diseases.","volume":"80","author":"J Lee","year":"2018","journal-title":"Acta Biomater."},{"key":"ref-117","article-title":"Work on DNA Vaccines Still Has a Way to Go","author":"J Kelvey","year":"2018"},{"key":"ref-118","doi-asserted-by":"publisher","first-page":"87-98","DOI":"10.1016\/j.virol.2005.01.019","article-title":"Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.","volume":"335","author":"M Rodriguez-Carreno","year":"2005","journal-title":"Virology."},{"key":"ref-119","doi-asserted-by":"publisher","first-page":"505-18","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!).","volume":"389","author":"A Henao-Restrepo","year":"2017","journal-title":"Lancet."},{"key":"ref-120","doi-asserted-by":"publisher","first-page":"857-66","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.","volume":"386","author":"A Henao-Restrepo","year":"2015","journal-title":"Lancet."},{"key":"ref-121","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(18)30560-9","article-title":"Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.","volume":"391","author":"W Metzger","year":"2018","journal-title":"Lancet."},{"key":"ref-122","doi-asserted-by":"publisher","first-page":"1647-60","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.","volume":"374","author":"S Agnandji","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.","volume":"9","author":"A Huttner","year":"2017","journal-title":"Sci Transl Med."},{"key":"ref-124","doi-asserted-by":"publisher","first-page":"8-16","DOI":"10.1016\/j.tim.2018.08.008","article-title":"Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?","volume":"27","author":"M Meyer","year":"2019","journal-title":"Trends Microbiol."},{"key":"ref-125","doi-asserted-by":"publisher","first-page":"6690-701","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.","volume":"88","author":"D Clarke","year":"2014","journal-title":"J Virol."},{"key":"ref-126","doi-asserted-by":"publisher","first-page":"S443-51","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.","volume":"212 Suppl 2","author":"D Matassov","year":"2015","journal-title":"J Infect Dis."},{"key":"ref-127","doi-asserted-by":"publisher","first-page":"688-91","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.","volume":"520","author":"C Mire","year":"2015","journal-title":"Nature."},{"key":"ref-128","doi-asserted-by":"publisher","first-page":"e01190-17","DOI":"10.1128\/JVI.01190-17","article-title":"Single Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.","volume":"92","author":"D Matassov","year":"2018","journal-title":"J Virol."},{"key":"ref-129","article-title":"CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines","year":"2018"},{"key":"ref-130","doi-asserted-by":"publisher","first-page":"2766-85","DOI":"10.3390\/v4112766","article-title":"Immune responses and Lassa virus infection.","volume":"4","author":"M Russier","year":"2012","journal-title":"Viruses."},{"key":"ref-131","doi-asserted-by":"publisher","first-page":"694-700","DOI":"10.4161\/hv.7.6.15198","article-title":"Argentine hemorrhagic fever vaccines.","volume":"7","author":"A Ambrosio","year":"2011","journal-title":"Hum Vaccin."},{"key":"ref-132","doi-asserted-by":"publisher","first-page":"103-15","DOI":"10.1016\/j.antiviral.2007.11.003","article-title":"New opportunities for field research on the pathogenesis and treatment of Lassa fever.","volume":"78","author":"S Khan","year":"2008","journal-title":"Antiviral Res."},{"key":"ref-133","doi-asserted-by":"publisher","first-page":"5-8","DOI":"10.1016\/j.cell.2016.06.029","article-title":"Roots, Not Parachutes: Research Collaborations Combat Outbreaks.","volume":"166","author":"N Yozwiak","year":"2016","journal-title":"Cell."},{"key":"ref-134","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.","volume":"9","author":"T Abreu-Mota","year":"2018","journal-title":"Nat Commun."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-134\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-134\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-134\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T22:45:34Z","timestamp":1606344334000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-134\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":134,"URL":"https:\/\/doi.org\/10.12688\/f1000research.16989.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18574.r43438","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18574.r43436","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18574.r43437","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-134\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18574.r43437, Hinh Ly, University of Minnesota - Twin Cities, St. Paul, Minnesota, 55108, USA, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-134\/v1#referee-response-43437","order":0,"name":"referee-response-43437","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18574.r43438, George O Akpede, Departments of Paediatrics, Irrua Specialist Teaching Hospital, Edo State, Nigeria, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-134\/v1#referee-response-43438","order":1,"name":"referee-response-43438","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18574.r43436, Gabriele Neumann, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-134\/v1#referee-response-43436","order":2,"name":"referee-response-43436","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was partially supported by grants R01AI093450 (ISL) and R56AI135770 (SP) from the National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}